Is Redhill Biopharma Stock a Good Investment?
Redhill Biopharma Investment Advice | RDHL |
- Examine Redhill Biopharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Redhill Biopharma's leadership team and their track record. Good management can help Redhill Biopharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Redhill Biopharma's business and its evolving consumer preferences.
- Compare Redhill Biopharma's performance and market position to its competitors. Analyze how Redhill Biopharma is positioned in terms of product offerings, innovation, and market share.
- Check if Redhill Biopharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Redhill Biopharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Redhill Biopharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Redhill Biopharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Redhill Biopharma Stock
Researching Redhill Biopharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 302.63. Redhill Biopharma had not issued any dividends in recent years. The entity had 1:25 split on the 20th of August 2024.
To determine if Redhill Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Redhill Biopharma's research are outlined below:
| Redhill Biopharma generated a negative expected return over the last 90 days | |
| Redhill Biopharma has high historical volatility and very poor performance | |
| Redhill Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Redhill Biopharma currently holds 1.17 M in liabilities with Debt to Equity (D/E) ratio of 9.89, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Redhill Biopharma has a current ratio of 0.96, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Redhill Biopharma's use of debt, we should always consider it together with its cash and equity. | |
| Redhill Biopharma currently holds about 28.86 M in cash with (35.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55. |
Redhill Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Redhill Biopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Redhill Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Redhill Biopharma's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.88 M.Basic technical analysis of Redhill Stock
As of the 23rd of March, Redhill Biopharma holds the Risk Adjusted Performance of (0.20), coefficient of variation of (435.57), and Variance of 23.24. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Redhill Biopharma, as well as the relationship between them. Please check Redhill Biopharma coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and skewness to decide if Redhill Biopharma is priced some-what accurately, providing market reflects its current price of 2.99 per share. Please also confirm Redhill Biopharma jensen alpha, which is currently at (1.05) to check out the company can sustain itself at a future point.Redhill Biopharma's Outstanding Corporate Bonds
Redhill Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Redhill Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Redhill bonds can be classified according to their maturity, which is the date when Redhill Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Redhill Biopharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Redhill Biopharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.20) | |||
| Market Risk Adjusted Performance | (1.14) | |||
| Mean Deviation | 3.42 | |||
| Coefficient Of Variation | (435.57) | |||
| Standard Deviation | 4.82 | |||
| Variance | 23.24 | |||
| Information Ratio | (0.22) | |||
| Jensen Alpha | (1.05) | |||
| Total Risk Alpha | (0.75) | |||
| Treynor Ratio | (1.15) | |||
| Maximum Drawdown | 24.06 | |||
| Value At Risk | (7.62) | |||
| Potential Upside | 5.5 | |||
| Skewness | 1.02 | |||
| Kurtosis | 3.41 |
| Risk Adjusted Performance | (0.20) | |||
| Market Risk Adjusted Performance | (1.14) | |||
| Mean Deviation | 3.42 | |||
| Coefficient Of Variation | (435.57) | |||
| Standard Deviation | 4.82 | |||
| Variance | 23.24 | |||
| Information Ratio | (0.22) | |||
| Jensen Alpha | (1.05) | |||
| Total Risk Alpha | (0.75) | |||
| Treynor Ratio | (1.15) | |||
| Maximum Drawdown | 24.06 | |||
| Value At Risk | (7.62) | |||
| Potential Upside | 5.5 | |||
| Skewness | 1.02 | |||
| Kurtosis | 3.41 |
Consider Redhill Biopharma's intraday indicators
Redhill Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Redhill Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Redhill Biopharma time-series forecasting models is one of many Redhill Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Redhill Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Redhill Stock media impact
Far too much social signal, news, headlines, and media speculation about Redhill Biopharma that are available to investors today. That information is available publicly through Redhill media outlets and privately through word of mouth or via Redhill internal channels. However, regardless of the origin, that massive amount of Redhill data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Redhill Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Redhill Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Redhill Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Redhill Biopharma alpha.
Redhill Biopharma Corporate Management
| Reza Fathi | Senior Development | Profile | |
| Kristin Comer | G VP | Profile | |
| Valerie Graceffa | VP Sales | Profile | |
| Razi Ingber | Chief Officer | Profile | |
| Rob Jackson | VP Marketing | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Redhill Biopharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.